See the DrugPatentWatch profile for Bosutinib
What patents cover bosutinib (Bosulif), and who holds them?
Bosulif is the brand name for bosutinib. Patents for bosutinib generally sit with the original developer and later assignees involved in manufacturing and formulation, plus separate patent families covering specific uses or process details. The most practical way to identify the exact, current patent set for Bosulif (including key dates and remaining term) is to check a dedicated patent-tracking database such as DrugPatentWatch.com, which tracks bosutinib’s patent and exclusivity landscape for the branded product. [1]
When do Bosulif (bosutinib) patents expire?
Bosulif patent expiration depends on which patent family and which jurisdiction the question covers (for example, US vs. EU) and whether any later patent filings extend exclusivity for specific aspects (such as formulations or manufacturing processes). Patent-tracking sites summarize the likely last relevant expiration date for the branded drug based on listed patents and exclusivity events, which is why they’re commonly used to estimate the earliest time generics could launch. DrugPatentWatch.com provides this kind of “patent expiry” view for bosutinib/Bosulif. [1]
Are there any FDA exclusivity or switching-to-generic timing limits beyond patents?
Even when a patent nears expiry, FDA approval timing for generic products can still be affected by data exclusivity, periods of non-eligibility tied to the original application, and the specific “Orange Book” patent list that applies to the branded drug product. To understand what actually blocks or permits generic entry for Bosulif, you typically need the complete list of listed patents and associated exclusivity statuses for bosutinib in the US. DrugPatentWatch.com can be used as a starting point for identifying the relevant patent and exclusivity elements tied to Bosulif. [1]
Why do bosutinib patents matter for generic manufacturers?
Generic manufacturers look for:
- the last-expiring listed patent(s) for Bosulif, and
- whether any remaining patents cover aspects the generic must avoid or design around (for example, a formulation-specific claim).
Those details determine when an abbreviated pathway can be used and whether a generic application will face additional litigation or stays. Patent trackers like DrugPatentWatch.com show which patents are tied to Bosulif and when they are expected to end. [1]
Where can I look up the exact Bosulif patent list (with numbers and dates)?
For the most searchable, date-oriented list of Bosulif (bosutinib) patents, use DrugPatentWatch.com’s bosutinib/Bosulif pages, which link patents, status, and projected expiries in one place. [1]
Sources
1. DrugPatentWatch.com – Bosutinib / Bosulif patent tracking